Highlights

The tumour-promoting activities of a famous protein

The tumour-promoting activities of a famous protein

Developing new cancer therapies and a more reliable test for prostate cancer are just some of the potential outcomes of Mauri...

read the full story

Newly funded research highlights MWC collaborations

Newly funded research highlights MWC collaborations

A five-year research programme aims to develop nontoxic vaccine technologies to complement existing cancer immunotherapies.

read the full story

Cancer drug advances to phase II clinical trials

Cancer drug advances to phase II clinical trials

A New Zealand cancer drug developed by two Maurice Wilkins Centre investigators has reached the second phase of clinical tria...

read the full story

New chemistry transforms cancer vaccine (2013)

New chemistry transforms cancer vaccine (2013)

A new kind of chemistry that dramatically simplifies the manufacture of cancer vaccines was created this year by Honours stud...

read the full story

New therapies - from a new generation (2013)

New therapies - from a new generation (2013)

Nurturing the next generation of scientists is an important part of the Maurice Wilkins Centre’s work – and senior students c...

read the full story

A licence to manufacture medicines (2012)

A licence to manufacture medicines (2012)

A licence to manufacture medicines has been granted to a University of Auckland facility that will produce the active ingredi...

read the full story

New Zealand patients trial local cancer drug (2012)

New Zealand patients trial local cancer drug (2012)

Cancer patients in Auckland, Waikato and the United States are participating in the first clinical trial of an exciting new d...

read the full story

The future of vaccines (2012)

The future of vaccines (2012)

Maurice Wilkins Centre investigator Professor Sarah Hook from the University of Otago is developing new vaccine formulations ...

read the full story

New drug targets treatment-resistant cancer (2011)

New drug targets treatment-resistant cancer (2011)

A new drug targeting an important group of cancer cells attracted international funding in 2011 and will soon enter clinical ...

read the full story

Exquisite networks (2011)

Exquisite networks (2011)

Innovative technology developed to study the heart has been adapted for a unique study of the immune system – and will now be...

read the full story

Cancer stealth drug enters clinical development (2010)

Cancer stealth drug enters clinical development (2010)

The first of an exciting new class of anticancer drugs will proceed to clinical development under an international deal annou...

read the full story

Drug selection a milestone for spin-out (2010)

Drug selection a milestone for spin-out (2010)

In 2010 Maurice Wilkins Centre investigators Professors Bill Denny and Peter Shepherd selected a new anticancer drug candidat...

read the full story

Doctoral students win international recognition (2010)

Doctoral students win international recognition (2010)

Two medicinal chemistry PhD students supervised by Maurice Wilkins Centre investigator Professor Margaret Brimble have won pr...

read the full story

Major new cancer vaccine programme (2010)

Major new cancer vaccine programme (2010)

Maurice Wilkins Centre investigators are involved in a major new research programme that aims to develop and trial anti-cance...

read the full story

Mapping cellular networks (2010)

Mapping cellular networks (2010)

Maurice Wilkins Centre PhD student Daniel Hurley and colleagues are mapping signalling networks in cancer and have identified...

read the full story

Lighting up lymph nodes (2009)

Lighting up lymph nodes (2009)

Maurice Wilkins Centre researchers have made exciting new discoveries about how human lymph nodes work.

read the full story

Kidney cancer researcher scores a first for New Zealand (2009)

Kidney cancer researcher scores a first for New Zealand (2009)

In December 2009, Maurice Wilkins Centre investigator Associate Professor Michael Hay became the first New Zealand scientist ...

read the full story